(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

Indolent Systemic Mastocytosis Clinical Trial

Official title:
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy

Status Active, not recruiting

Clinical Trial Summary

This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. The study will be conducted in 3 parts. All patients will receive treatment with avapritinib during Part 3 including those rolling over from the placebo group.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03731260
Study type	Interventional
Source	Blueprint Medicines Corporation
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	April 16, 2019
Completion date	January 31, 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04655118` - Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis	Phase 2
Recruiting	`NCT04910685` - (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis	Phase 2/Phase 3
Completed	`NCT03632811` - Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French Language
Completed	`NCT02808793` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002	Phase 1
Completed	`NCT02478957` - Treatment of Indolent Systemic Mastocytosis With PA101	Phase 2
Completed	`NCT03770273` - Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis	Phase 2
Recruiting	`NCT04333108` - Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment	Phase 3
Not yet recruiting	`NCT06210698` - Angioedema Biomarker Research Study
Completed	`NCT00814073` - Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis	Phase 3
Active, not recruiting	`NCT01920204` - Midostaurin in Indolent Systemic Mastocytosis	Phase 2